Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection
Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and comm...
Gespeichert in:
| Veröffentlicht in: | Journal of Drug Delivery 2016-01, Vol.2016, p.3-7 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | |
| container_start_page | 3 |
| container_title | Journal of Drug Delivery |
| container_volume | 2016 |
| creator | Abrishami, Mojtaba Abrishami, Majid Mahmoudi, Asma Mosallaei, Navid Vakili Ahrari Roodi, Mohammad Malaekeh-Nikouei, Bizhan |
| description | Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (p |
| doi_str_mv | 10.1155/2016/1368481 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5075616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A502000508</galeid><airiti_id>P20151203006_201612_201709060018_201709060018_3_7</airiti_id><sourcerecordid>A502000508</sourcerecordid><originalsourceid>FETCH-LOGICAL-a513t-c0f702c5ca5eaba5519451050ab9fa3c8914c8497527106be00e1834354e2a1d3</originalsourceid><addsrcrecordid>eNqFktuLEzEUxgdR3GXdN59lQBBBu3uSTObyIpT1soWigpfXcJqe2WZJk26Sqex_b8bWsgXBBHL9nS_JyVcUzxlcMCblJQdWXzJRt1XLHhWnHDqYCOD88WHMqpPiPMZbyKVqoWvgaXHCmxZEy-RpQd-8Nctybja5_YzObzAkoy3FcrbeBL-lMq2ofJ-XfE8OdTndorG4MNak-9K48qdJgfwQS-wThXLmUkCvB4vj-JZ0Mt49K570aCOd7_uz4sfHD9-vrifzL59mV9P5BCUTaaKhb4BrqVESLlBK1lWSgQRcdD0K3Xas0m3VNZI3DOoFARBrRSVkRRzZUpwV73a6m2GxpqWm8TJWbYJZY7hXHo063nFmpW78VkloZM3qLPB6LxD83UAxqbWJmqxFN75R5dOkFIw1IqMvd-gNWlLG9T4r6hFXUwk8p1tCm6mLf1C5LmlttHfUm7x-FPDqQcCK0KZV9HYY0xiPwbc7UAcfY6D-8EwGajSHGs2h9ubI-IuHqTnAf62QgTc7YGXcEn-Z_8ld72g0wSSjbv0QXP5a9TVjknEQAPWfEMbHrslurAFYezwRqhG_ATlH0wQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835531173</pqid></control><display><type>article</type><title>Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection</title><source>Wiley-Blackwell Open Access Titles</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Abrishami, Mojtaba ; Abrishami, Majid ; Mahmoudi, Asma ; Mosallaei, Navid ; Vakili Ahrari Roodi, Mohammad ; Malaekeh-Nikouei, Bizhan</creator><contributor>Cavalli, Roberta</contributor><creatorcontrib>Abrishami, Mojtaba ; Abrishami, Majid ; Mahmoudi, Asma ; Mosallaei, Navid ; Vakili Ahrari Roodi, Mohammad ; Malaekeh-Nikouei, Bizhan ; Cavalli, Roberta</creatorcontrib><description>Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (p<0.05). Diclofenac was quantified in samples up to 48 hours after intraocular injection. Four hours after intravitreal injection, the concentration of diclofenac in vitreous and aqueous humor of eyes receiving SLNs was, respectively, 2.5 and 6.5 times higher than eyes injected with commercial form of drug. Conclusions. Here, we demonstrate the potential of SLNs as a carrier of diclofenac for intraocular injection in order to prevent the systemic effects of the drug, increase the injection intervals, and improve the patient compliance.</description><identifier>ISSN: 2090-3014</identifier><identifier>EISSN: 2090-3022</identifier><identifier>DOI: 10.1155/2016/1368481</identifier><identifier>PMID: 27803815</identifier><language>eng</language><publisher>Egypt: Hindawi Limiteds</publisher><subject>Complications and side effects ; Diclofenac ; Dosage and administration ; Drug delivery systems ; Drugs ; Nanoparticles ; Physiological aspects ; Properties ; Vehicles</subject><ispartof>Journal of Drug Delivery, 2016-01, Vol.2016, p.3-7</ispartof><rights>Copyright © 2016 Mojtaba Abrishami et al.</rights><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><rights>Copyright © 2016 Mojtaba Abrishami et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a513t-c0f702c5ca5eaba5519451050ab9fa3c8914c8497527106be00e1834354e2a1d3</citedby><cites>FETCH-LOGICAL-a513t-c0f702c5ca5eaba5519451050ab9fa3c8914c8497527106be00e1834354e2a1d3</cites><orcidid>0000-0002-1908-9530 ; 0000-0003-2001-7929 ; 0000-0003-1180-3944 ; 0000-0001-7329-6066</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075616/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075616/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27803815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Cavalli, Roberta</contributor><creatorcontrib>Abrishami, Mojtaba</creatorcontrib><creatorcontrib>Abrishami, Majid</creatorcontrib><creatorcontrib>Mahmoudi, Asma</creatorcontrib><creatorcontrib>Mosallaei, Navid</creatorcontrib><creatorcontrib>Vakili Ahrari Roodi, Mohammad</creatorcontrib><creatorcontrib>Malaekeh-Nikouei, Bizhan</creatorcontrib><title>Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection</title><title>Journal of Drug Delivery</title><addtitle>J Drug Deliv</addtitle><description>Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (p<0.05). Diclofenac was quantified in samples up to 48 hours after intraocular injection. Four hours after intravitreal injection, the concentration of diclofenac in vitreous and aqueous humor of eyes receiving SLNs was, respectively, 2.5 and 6.5 times higher than eyes injected with commercial form of drug. Conclusions. Here, we demonstrate the potential of SLNs as a carrier of diclofenac for intraocular injection in order to prevent the systemic effects of the drug, increase the injection intervals, and improve the patient compliance.</description><subject>Complications and side effects</subject><subject>Diclofenac</subject><subject>Dosage and administration</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Nanoparticles</subject><subject>Physiological aspects</subject><subject>Properties</subject><subject>Vehicles</subject><issn>2090-3014</issn><issn>2090-3022</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNqFktuLEzEUxgdR3GXdN59lQBBBu3uSTObyIpT1soWigpfXcJqe2WZJk26Sqex_b8bWsgXBBHL9nS_JyVcUzxlcMCblJQdWXzJRt1XLHhWnHDqYCOD88WHMqpPiPMZbyKVqoWvgaXHCmxZEy-RpQd-8Nctybja5_YzObzAkoy3FcrbeBL-lMq2ofJ-XfE8OdTndorG4MNak-9K48qdJgfwQS-wThXLmUkCvB4vj-JZ0Mt49K570aCOd7_uz4sfHD9-vrifzL59mV9P5BCUTaaKhb4BrqVESLlBK1lWSgQRcdD0K3Xas0m3VNZI3DOoFARBrRSVkRRzZUpwV73a6m2GxpqWm8TJWbYJZY7hXHo063nFmpW78VkloZM3qLPB6LxD83UAxqbWJmqxFN75R5dOkFIw1IqMvd-gNWlLG9T4r6hFXUwk8p1tCm6mLf1C5LmlttHfUm7x-FPDqQcCK0KZV9HYY0xiPwbc7UAcfY6D-8EwGajSHGs2h9ubI-IuHqTnAf62QgTc7YGXcEn-Z_8ld72g0wSSjbv0QXP5a9TVjknEQAPWfEMbHrslurAFYezwRqhG_ATlH0wQ</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Abrishami, Mojtaba</creator><creator>Abrishami, Majid</creator><creator>Mahmoudi, Asma</creator><creator>Mosallaei, Navid</creator><creator>Vakili Ahrari Roodi, Mohammad</creator><creator>Malaekeh-Nikouei, Bizhan</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><scope>188</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1908-9530</orcidid><orcidid>https://orcid.org/0000-0003-2001-7929</orcidid><orcidid>https://orcid.org/0000-0003-1180-3944</orcidid><orcidid>https://orcid.org/0000-0001-7329-6066</orcidid></search><sort><creationdate>20160101</creationdate><title>Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection</title><author>Abrishami, Mojtaba ; Abrishami, Majid ; Mahmoudi, Asma ; Mosallaei, Navid ; Vakili Ahrari Roodi, Mohammad ; Malaekeh-Nikouei, Bizhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a513t-c0f702c5ca5eaba5519451050ab9fa3c8914c8497527106be00e1834354e2a1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Complications and side effects</topic><topic>Diclofenac</topic><topic>Dosage and administration</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Nanoparticles</topic><topic>Physiological aspects</topic><topic>Properties</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abrishami, Mojtaba</creatorcontrib><creatorcontrib>Abrishami, Majid</creatorcontrib><creatorcontrib>Mahmoudi, Asma</creatorcontrib><creatorcontrib>Mosallaei, Navid</creatorcontrib><creatorcontrib>Vakili Ahrari Roodi, Mohammad</creatorcontrib><creatorcontrib>Malaekeh-Nikouei, Bizhan</creatorcontrib><collection>Airiti Library</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Drug Delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abrishami, Mojtaba</au><au>Abrishami, Majid</au><au>Mahmoudi, Asma</au><au>Mosallaei, Navid</au><au>Vakili Ahrari Roodi, Mohammad</au><au>Malaekeh-Nikouei, Bizhan</au><au>Cavalli, Roberta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection</atitle><jtitle>Journal of Drug Delivery</jtitle><addtitle>J Drug Deliv</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><spage>3</spage><epage>7</epage><pages>3-7</pages><issn>2090-3014</issn><eissn>2090-3022</eissn><abstract>Purpose. In order to improve the drug availability after intravitreal administration, solid lipid nanoparticles (SLNs) containing diclofenac were prepared. Methods. In this experimental study, 18 albino rabbits were included. In right and left eyes of all rabbits, SLNs containing diclofenac and commercial form of diclofenac (0.3 mg drug) were intravitreally injected, respectively. One, four, twelve, twenty-four, and forty-eight hours after injection, vitreous and aqueous humor samples were obtained in all cases. Then, the concentration of diclofenac sodium was evaluated in all samples. Results. Size of nanoparticles was around 170 nm after preparation. Drug concentration in eyes injected with SLNs was significantly higher than left eyes injected with commercial formulation up to 4 hours after intravitreal injection (p<0.05). Diclofenac was quantified in samples up to 48 hours after intraocular injection. Four hours after intravitreal injection, the concentration of diclofenac in vitreous and aqueous humor of eyes receiving SLNs was, respectively, 2.5 and 6.5 times higher than eyes injected with commercial form of drug. Conclusions. Here, we demonstrate the potential of SLNs as a carrier of diclofenac for intraocular injection in order to prevent the systemic effects of the drug, increase the injection intervals, and improve the patient compliance.</abstract><cop>Egypt</cop><pub>Hindawi Limiteds</pub><pmid>27803815</pmid><doi>10.1155/2016/1368481</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1908-9530</orcidid><orcidid>https://orcid.org/0000-0003-2001-7929</orcidid><orcidid>https://orcid.org/0000-0003-1180-3944</orcidid><orcidid>https://orcid.org/0000-0001-7329-6066</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2090-3014 |
| ispartof | Journal of Drug Delivery, 2016-01, Vol.2016, p.3-7 |
| issn | 2090-3014 2090-3022 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5075616 |
| source | Wiley-Blackwell Open Access Titles; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Complications and side effects Diclofenac Dosage and administration Drug delivery systems Drugs Nanoparticles Physiological aspects Properties Vehicles |
| title | Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A18%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Solid%20Lipid%20Nanoparticles%20Improve%20the%20Diclofenac%20Availability%20in%20Vitreous%20after%20Intraocular%20Injection&rft.jtitle=Journal%20of%20Drug%20Delivery&rft.au=Abrishami,%20Mojtaba&rft.date=2016-01-01&rft.volume=2016&rft.spage=3&rft.epage=7&rft.pages=3-7&rft.issn=2090-3014&rft.eissn=2090-3022&rft_id=info:doi/10.1155/2016/1368481&rft_dat=%3Cgale_pubme%3EA502000508%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835531173&rft_id=info:pmid/27803815&rft_galeid=A502000508&rft_airiti_id=P20151203006_201612_201709060018_201709060018_3_7&rfr_iscdi=true |